Patents by Inventor Robin Callan

Robin Callan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9216247
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: December 22, 2015
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
  • Publication number: 20150246167
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: January 8, 2010
    Publication date: September 3, 2015
    Applicant: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
  • Publication number: 20150246168
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: January 8, 2010
    Publication date: September 3, 2015
    Applicant: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
  • Publication number: 20150083664
    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.
    Type: Application
    Filed: October 6, 2014
    Publication date: March 26, 2015
    Inventors: Robin Callan, James J. Cole
  • Publication number: 20140328948
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: December 6, 2013
    Publication date: November 6, 2014
    Applicant: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
  • Patent number: 8864699
    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: October 21, 2014
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, James J. Cole
  • Publication number: 20140034873
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicant: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole
  • Publication number: 20120006748
    Abstract: Dry acid-concentrate compositions comprising citrate and their use in preparing dialysate compositions and in performing hemodialysis is disclosed.
    Type: Application
    Filed: December 21, 2010
    Publication date: January 12, 2012
    Applicant: ADVANCED RENAL TECHNOLOGIES
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
  • Publication number: 20110172583
    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.
    Type: Application
    Filed: December 20, 2010
    Publication date: July 14, 2011
    Applicant: Advanced Renal Technologies
    Inventors: Robin CALLAN, James J. Cole
  • Patent number: 7862530
    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.
    Type: Grant
    Filed: November 8, 2004
    Date of Patent: January 4, 2011
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, James J. Cole
  • Publication number: 20100176340
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: January 8, 2010
    Publication date: July 15, 2010
    Applicant: ADVANCED RENAL TECHNOLOGIES
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
  • Publication number: 20100170849
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: January 8, 2010
    Publication date: July 8, 2010
    Applicant: ADVANCED RENAL TECHNOLOGIES
    Inventors: Robin Callan, Walter A. Van Schalkwijk, James J. Cole, Suhail Ahmad
  • Patent number: 7670491
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: March 2, 2010
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole, Suhail Ahmad
  • Publication number: 20050119598
    Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.
    Type: Application
    Filed: November 8, 2004
    Publication date: June 2, 2005
    Applicant: Advanced Renal Technologies
    Inventors: Robin Callan, James Cole
  • Publication number: 20040060865
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Application
    Filed: June 24, 2003
    Publication date: April 1, 2004
    Inventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole, Suhail Ahmad
  • Patent number: 6610206
    Abstract: Acid concentrates, and dialysate compositions prepared therefrom, contain citric acid and an effective amount of a buffering agent selected from acetate and/or lactate. The buffering agent allows a physiologically acceptable amount of citrate to maintain the desired pH of the dialysate.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: August 26, 2003
    Assignee: Advanced Renal Technologies
    Inventors: Robin Callan, Walter A. van Schalkwijk, James J. Cole